Observational study evaluates virologic outcomes in key populations with HIV switched to dolutegravir, highlighting strategies to achieve rapid viral suppression.
Achieving optimal virologic suppression among key population groups is essential to HIV epidemic control. The recommendation to transition HIV positive key populations from efavirenz-based regimen (Tenofovir, Lamivudine, Efavirenz (TLE)) to dolutegravir-based regimen (Tenofovir, Lamivudine, Dolutegravir (TLD)) considered the effectiveness of dolutegravir in achieving suppressed viral loads within a short period of time. The aim of this study was to investigate the virologic outcome of key populations (KP) transitioned to dolutegravir-based regimen.
No takes yet. Share an insight, caveat, or question.
Katbi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: